Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Pentadeca Arginate (PDA) | TB-500 (Thymosin Beta-4) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection. | Research indicates 2-2.5 mg administered twice weekly via subcutaneous injection. |
| Timing | Administer on an empty stomach. Inject near site of injury for localized effect. | No strict timing requirements. Can be administered at any time of day. Systemic action means injection location is not critical. |
| Cycle Duration | 4-12 weeks depending on therapeutic target. | Loading phase: 4-6 weeks. Total cycle: 8-16 weeks. |
| Evidence Level | animal_plus_anecdotal | animal_plus_anecdotal |
Pentadeca Arginate is a synthetic 15-amino acid peptide utilizing an arginate salt formulation of the BPC-157 sequence, designed to enhance nitric oxide production and promote angiogenesis. It stimulates collagen synthesis, enhances tissue repair through increased tensile strength, reduces inflammation via modulation of inflammatory cytokines, and accelerates cellular proliferation in tendon fibroblasts. The arginate salt form provides superior stability and bioavailability compared to traditional acetate formulations.
Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection.
Administer on an empty stomach. Inject near site of injury for localized effect.
4-12 weeks depending on therapeutic target.
TB-500 is a synthetic fragment of Thymosin Beta-4, a 43-amino acid protein that sequesters G-actin monomers, preventing premature polymerization and facilitating cellular migration and morphological changes essential for wound healing. It upregulates actin to promote cell migration, proliferation, and differentiation of stem/progenitor cells at injury sites. TB-500 also enhances angiogenesis, reduces inflammation, and promotes tissue remodeling through increased re-epithelialization and vascular density.
Research indicates 2-2.5 mg administered twice weekly via subcutaneous injection.
No strict timing requirements. Can be administered at any time of day. Systemic action means injection location is not critical.
Loading phase: 4-6 weeks. Total cycle: 8-16 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →